Detailed Information on Publication Record
2024
Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
SVATON, Martin, Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK et. al.Basic information
Original name
Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
Authors
SVATON, Martin (203 Czech Republic), Magdalena KNETKI-WROBLEWSKA, Sylwia TABOR, Petr DOMECKY, Ondřej VENCLÍČEK (203 Czech Republic, belonging to the institution), Jana KREJCI (203 Czech Republic), Marie DROSSLEROVA (203 Czech Republic), Michal HRNCIARIK (203 Czech Republic), Daniel HRICISAK (203 Czech Republic), Alzbeta BEJCKOVA (203 Czech Republic), Ondrej FISCHER (203 Czech Republic), Martina VITKOVA (203 Czech Republic) and Maciej KRZAKOWSKI
Edition
In vivo, Athens, International Institute of Anticancer Research, 2024, 0258-851X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30203 Respiratory systems
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.300 in 2022
Organization unit
Faculty of Medicine
UT WoS
001300248100042
Keywords in English
Non-small cell lung cancer; pembrolizumab; overall survival; PD-L1 expression
Tags
International impact, Reviewed
Změněno: 23/9/2024 13:16, Mgr. Tereza Miškechová
Abstract
V originále
Background/Aim: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression >= 50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (>= 50%) >= 50%) in patients with NSCLC. Patients and Methods: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression >= 50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. Results: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD- L1 in the Cox regression model including the effect covariates. Conclusion: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD- L1 >= 50% >= 50% treated with pembrolizumab.